HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Separation Key To Posting Studies Linking Dietary Ingredients To Preventing Or Treating Disease

Executive Summary

DSHEA’s Scientific Literature Exemption is attracting attention for offering online studies showing nutrients’ benefits on diseases including COVID-19, though the method isn’t free of risks, suggests CRN executive Megan Olsen.

You may also be interested in...



US Supplement Industry Rides Growth Amid Changes After Year Of Covid-19 Pandemic

“Many of those initial fears have abated as companies have learned more about transmission and how to protect staff,” says Tara Couch, EAS Consulting. But industry is changed and manufacturers are thinking more intently about supply chains and manufacturing processes.

Warnings Note Disease Treatment Studies Placed Too Close To Supplements For US FDA’s Comfort

Dietary ingredients identified in recent FDA warning letters as linked to disease claims by marketers directing customers to scientific literature include omega-3 fatty acid, ginkgo biloba, glucosamine curcumin and vitamin D.

UK Government Backs Vitamin D COVID Benefits With Supplement Handout

By handing out free supplements to the clinically vulnerable, the UK government is effectively endorsing the use of vitamin D to reduce the risk and/or severity of COVID-19, although it says more research is needed.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel